国泰海通证券股份有限公司 关于杭州可靠护理用品股份有限公司部分募投项目结项 并将节余募集资金永久补充流动资金的核查意见 2、公司于 2024 年 4 月 26 日召开了第五届董事会第三次会议、第五届监事 会第三次会议，并经 2024 年 5 月 24 日召开的 2023 年度股东大会审议，通过了 《关于将部分募集资金永久补充流动资金、部分募集资金项目延期的议案》，同 意公司将"智能工厂建设项目"部分募集资金永久补充流动资金及其部分项目延 期至 2025 年 6 月 30 日之前支付，并将"技术研发中心升级建设项目"和"品牌 推广项目"募集资金项目延期。 三、本次结项的募投项目资金使用及节余情况 国泰海通证券股份有限公司（以下简称"保荐机构"或"国泰海通"，曾用 名"国泰君安证券股份有限公司"）作为杭州可靠护理用品股份有限公司（以下 简称"可靠股份"或"公司"）首次公开发行股票并在创业板上市的保荐机构， 根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 ...

目 录 | 一、审计报告……………………………………………………… 第 | 1—6 | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | | 页 | | （一）合并资产负债表…………………………………………… | 第 7 | 页 | | （二）母公司资产负债表………………………………………… | 第 8 | 页 | | （三）合并利润表………………………………………………… | 第 9 | 页 | | （四）母公司利润表………………………………………………第 | 10 | 页 | | （五）合并现金流量表……………………………………………第 | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | 14 | 页 | | | | 审 计 报 告 天健审〔2025〕6758 号 杭州可靠护理用品股份有限公司全体股东： 一、审计意见 我们审计了杭 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 280,180,366.57, a decrease of 0.98% compared to CNY 282,967,455.35 in the same period last year[6] - Net profit attributable to shareholders was CNY 18,589,628.07, reflecting a 1.41% increase from CNY 18,331,987.65 year-on-year[6] - Basic earnings per share increased by 3.56% to CNY 0.0698, up from CNY 0.0674 in the same period last year[6] - Operating profit increased to ¥21,892,829.70, compared to ¥20,801,784.53 in the previous period, marking a growth of 5.24%[24] - Net profit for the current period is ¥18,614,887.13, slightly up from ¥18,204,327.14, representing an increase of 2.25%[25] Cash Flow - The net cash flow from operating activities surged by 112.42% to CNY 29,167,275.17, compared to CNY 13,731,198.53 in the previous year[12] - Cash received from sales and services was ¥267,053,603.28, down from ¥269,780,463.66, a decrease of 1.01%[27] - Net cash flow from operating activities was $29,167,275.17, an increase from $13,731,198.53 in the previous period, reflecting a positive trend in operational efficiency[28] - Total cash inflow from investment activities amounted to $112,033,319.66, significantly higher than $4,600,000.00 in the prior period, indicating strong investment recovery[28] - Cash outflow from investment activities was $8,585,517.35, down from $28,529,423.70, leading to a net cash flow from investment activities of $103,447,802.31, a substantial improvement[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,093,650,724.41, a slight increase of 0.20% from CNY 2,089,561,649.59 at the end of the previous year[6] - Total current assets increased to ¥1,292,528,954.09 from ¥1,275,660,793.30[19] - Total non-current assets decreased to ¥801,121,770.32 from ¥813,900,856.29[19] - Total liabilities increased, with short-term borrowings at ¥100,329,163.01[20] - Total liabilities decreased to ¥663,532,058.13 from ¥678,058,135.61, a reduction of 2.16%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,358[15] - Major shareholder Jin Liwei holds 30.13% of shares, totaling 81,909,282 shares[15] - Major shareholder Bao Jia holds 29.13% of shares, totaling 79,190,682 shares[15] Research and Development - Research and development expenses rose by 15.34% to CNY 11,782,913.68, indicating a focus on innovation[12] - Research and development expenses rose to ¥11,782,913.68 from ¥10,215,780.02, an increase of 15.37%[24] Investment Income - The company reported a significant increase in investment income, reaching CNY 2,122,287.33, compared to a loss of CNY 885,966.04 in the previous year[12]

Financial Performance - The company's operating revenue for 2024 was ¥1,078,536,317.41, a decrease of 0.27% compared to ¥1,081,484,375.42 in 2023[26]. - Net profit attributable to shareholders for 2024 was ¥31,172,830.98, representing a significant increase of 54.44% from ¥20,184,911.13 in 2023[26]. - The net profit after deducting non-recurring gains and losses was ¥24,068,826.91, up 33.06% from ¥18,088,289.05 in 2023[26]. - The net cash flow from operating activities decreased by 76.97% to ¥52,441,537.27 from ¥227,702,913.25 in 2023[26]. - The total assets at the end of 2024 were ¥2,089,561,649.59, an increase of 4.90% from ¥1,992,017,074.35 at the end of 2023[26]. - Total revenue for 2024 was CNY 1,078,536,317.4, a slight decrease of 0.27% compared to CNY 1,081,484,375.4 in 2023[103]. - Adult incontinence products generated CNY 557,868,016.80, accounting for 51.72% of total revenue, down 1.33% year-over-year[103]. - Baby care products saw a revenue increase of 6.82%, reaching CNY 415,977,441.30, representing 38.57% of total revenue[103]. - Domestic sales increased by 2.66% to CNY 625,921,655.16, while overseas sales decreased by 4.06% to CNY 452,614,662.25[103]. Market Position and Strategy - The company is committed to becoming a world-class leader in the health care industry, with a focus on innovation and market expansion[5]. - The company is actively involved in research and development of new products and technologies to enhance its market position[5]. - The company is committed to expanding its market presence in the adult incontinence product sector to meet the growing demand from various consumer segments[39]. - The company ranked first in the domestic adult incontinence products market and its "Reliable" brand has been the top-selling product on e-commerce platforms for several consecutive years[42]. - The company has established a strong brand image in the disposable hygiene products market, focusing on adult incontinence care and elderly services[40]. - The company has a comprehensive sales model that includes both online and offline channels, partnering with major retailers like Walmart and leveraging e-commerce platforms such as Tmall and JD[63]. - The company is positioned to benefit from the increasing demand for elderly care services and products due to the aging population and supportive government policies[72]. Research and Development - The company holds a total of 251 authorized patents, including 63 invention patents, and has been involved in over 20 key research projects, enhancing its technological capabilities[43]. - The company is developing new products, including biodegradable hygiene products and high-absorption composite cores for diapers, which are expected to enhance product competitiveness[113]. - R&D investment amounted to ¥45,039,973.07 in 2024, representing 4.18% of operating revenue, an increase from 4.08% in 2023[113]. - The company aims to enhance its product structure and increase R&D investment to meet the growing demand in the aging population market[72]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the report's approval[7]. - The company has a complete governance structure, maintaining independence from its controlling shareholders in assets, personnel, finance, and operations[162]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with relevant regulations[157]. - The company has established independent financial decision-making and accounting practices[163]. - The company has a dedicated investor relations management strategy, fostering long-term relationships with investors[160]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[153]. Employee and Management - The total number of employees at the end of the reporting period is 674, with 338 in the parent company and 336 in major subsidiaries[188]. - The company plans to implement various training programs in 2024, including EMBA courses, to enhance employee skills and align with strategic goals[190]. - The company has established a performance evaluation mechanism to enhance employee motivation and align organizational goals[189]. - Total compensation for directors, supervisors, and senior management in 2024 amounted to 7.6611 million yuan[178]. Challenges and Risks - The company faces increasing market competition and significant fluctuations in raw material prices, which pose risks to future development[8]. - The penetration rate of adult incontinence products in China is extremely low, estimated at less than 10%, compared to over 50% in Japan and the US[71]. - The company has acknowledged that changes in market conditions, such as declining birth rates, have impacted the efficiency of fund usage for the smart factory project[133]. Community Engagement and Social Responsibility - The company actively participated in community outreach and public welfare activities, enhancing brand recognition among target demographics[95]. - The company intends to enhance user engagement through offline promotions and community projects, building a valuable user operation system[142]. Future Outlook - Future guidance remains optimistic, with expectations for continued revenue growth, although exact figures were not provided[169]. - The company is committed to improving its operational efficiency and exploring new market opportunities as part of its long-term strategy[169].

杭州可靠护理用品股份有限公司 独立董事 2024 年度述职报告 本人肖炜麟，作为杭州可靠护理用品股份有限公司（以下简称"公司"）的 第五届董事会独立董事，在任职期间严格按照证监会《上市公司独立董事管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关法律、法规以及《公司章程》 《公司独立董事制度》等公司制度的规定和要求，勤勉尽责、独立谨慎地行使权 利，积极出席相关会议，客观、公正、审慎地对公司重大事项发表独立意见或事 前认可意见，切实维护公司和全体股东尤其是中小股东的合法权益。现将本人 2024 年度履行独立董事职责的情况总结如下： 一、独立董事的基本情况 本人肖炜麟，1981 年生，中国国籍，无境外永久居住权，华南理工大学财 务管理专业博士学历，中共党员。2012 年至今，任职于浙江大学管理学院，先 后担任讲师和副教授。现任浙江大学管理学院财务与会计学系副教授、博士生导 师，浙江大学资本市场研究中心副主任、浙江省金融研究院特聘研究员。现任安 邦护卫集团股份有限公司、兴源环境科技股份有限公司独立董事。2024 年 1 月 起担任公司第 ...

杭州可靠护理用品股份有限公司 独立董事 2024 年度述职报告 本人朱茶芬，作为杭州可靠护理用品股份有限公司（以下简称"公司"）的 第四届董事会独立董事，在任职期间严格按照证监会《 上市公司独立董事管理办 法》 深圳证券交易所创业板股票上市规则》 深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关法律、法规以及 公司章程》 公司独立董事制度》等公司制度的规定和要求，勤勉尽责、独立谨慎地行使权 利，积极出席相关会议，客观、公正、审慎地对公司重大事项发表独立意见或事 前认可意见，切实维护公司和全体股东尤其是中小股东的合法权益。现将本人 2024 年度任职期间履行独立董事职责情况总结如下： 一、独立董事的基本情况 本人朱茶芬，1980 年生，中国国籍，无境外居留权，中国注册会计师，上海 财经大学会计学博士学历，浙江大学工商管理博士后。现任浙江大学管理学院副 教授，以及振德医疗用品股份有限公司独立董事、杭州广立微电子股份有限公司 独立董事、浙江中控信息产业股份有限公司独立董事,浙江德施曼科技智能股份 有限公司独立董事。2018 年 1 月 21 日至 2024 年 1 月 19 日，担任 ...

杭州可靠护理用品股份有限公司 独立董事 2024 年度述职报告 本人杜健，作为杭州可靠护理用品股份有限公司（以下简称"公司"）的第 四届董事会独立董事，在任职期间严格按照证监会《 上市公司独立董事管理办法》 深圳证券交易所创业板股票上市规则》 深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关法律、法规以及《 公司章程》 公 司独立董事制度》等公司制度的规定和要求，勤勉尽责、独立谨慎地行使权利， 积极出席相关会议，客观、公正、审慎地对公司重大事项发表独立意见或事前认 可意见，切实维护公司和全体股东尤其是中小股东的合法权益。现将本人 2024 年度任职期间履行独立董事职责情况总结如下： 一、独立董事的基本情况 本人杜健，1978 年生，中国国籍，无境外永久居留权，浙江大学管理科学与 工程博士研究生。2006 年至今，任职于浙江大学管理学院，先后担任浙江大学管 理科学与工程系博士后、讲师以及副教授，现任浙江大学创新创业与战略学系教 授。2018 年 1 月 21 日至 2024 年 1 月 19 日，担任公司独立董事，现因任期届满 已离任。 2024 年度任职期间，本人任职符合《 上 ...

杭州可靠护理用品股份有限公司 独立董事 2024 年度述职报告 本人寿泓，作为杭州可靠护理用品股份有限公司（以下简称"公司"）的第 五届董事会独立董事，在任职期间严格按照证监会《 上市公司独立董事管理办法》 深圳证券交易所创业板股票上市规则》 深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等有关法律、法规以及《 公司章程》 公 司独立董事制度》等公司制度的规定和要求，勤勉尽责、独立谨慎地行使权利， 积极出席相关会议，客观、公正、审慎地对公司重大事项发表独立意见或事前认 可意见，切实维护公司和全体股东尤其是中小股东的合法权益。现将本人 2024 年度履行独立董事职责的情况总结如下： 一、独立董事的基本情况 本人寿泓，1955 年生，中国国籍，无境外永久居住权，大专学历。1980 年 至 2005 年，担任浙江省轻工业厅科员，2005 年至 2011 年，从事设备进出口代 理工作；2011 年至今，担任杭州思悦达进出口有限公司监事；2021 年 3 月至今， 担任杭州牧也科技有限公司监事；2023 年 11 月至今，担任杭州博源供应链有限 公司监事。现任公司第五届董事会独立董事、提名委 ...

杭州可靠护理用品股份有限公司 独立董事 2024 年度述职报告 本人景乃权，作为杭州可靠护理用品股份有限公司（以下简称"公司"）的 第五届董事会独立董事，在任职期间严格按照证监会《 上市公司独立董事管理办 法》 深圳证券交易所创业板股票上市规则》 深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关法律、法规以及 公司章程》 公司独立董事制度》等公司制度的规定和要求，认真履行了独立董事的职责， 恪尽职守，勤勉尽责，积极出席相关会议，认真仔细审阅会议议案及相关材料， 积极参与各项议题的讨论并提出了合理建议，充分发挥了独立董事作用，切实维 护公司和全体股东尤其是中小股东的合法权益。现将本人 2024 年度履行独立董 事职责的情况总结如下： 一、独立董事的基本情况 本人景乃权，1962 年生，中国国籍，硕士学历，无境外居留权，民建会员， 新华社特约经济分析师，浙江省公共政策研究院研究员。曾任浙江大学金融系副 教授、硕士生导师，浙江大学金融投资研究中心副主任、浙江大学江万龄黄金投 资研究所所长，浙江大学求是经济技术咨询有限公司董事长兼总经理，广东发展 银行杭州分行高级顾问等。主持国家社科基 ...

杭州可靠护理用品股份有限公司（以下简称"公司"）根据《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》 以及公司相关会计政策的规定，计提了信用减值准备及资产减值准备，现将具体 情况公告如下： 一、计提信用减值准备及资产减值准备情况概述 （一）本次信用减值准备及资产减值准备的原因 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《企业会计准则》以及公司相关会计政策的规定，对合并范围内截至 2024 年末的各类资产进行全面清查，并进行充分的评估和分析。经资产减值测试，公 司认为部分资产存在一定的减值迹象，基于谨慎性原则，公司对存在减值迹象的 相关资产计提信用减值准备及资产减值准备。 证券代码：301009 证券简称：可靠股份 公告编号：2025-015 （二）本次计提减值准备的资产范围和总金额 杭州可靠护理用品股份有限公司 经公司及子公司对截至 2024 年 12 月 31 日存在可能发生减值迹象的资产进 行全面清查和资产减值测试后，2024 年度计提信用减值准备及资产减值准备共 计 15,465,141.08 元，计入的报告期间为 202 ...